Medical-economic Evaluation Comparing Intensive Outpatient Monitoring of Neuro-cardiovascular Diseases by Nurses, Doctors and Hospital and Private-sector Pharmacists, Compared to Usual Monitoring.

NCT ID: NCT04188457

Last Updated: 2025-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

859 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-15

Study Completion Date

2025-10-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cerebral Vascular Accidents (stroke) and Myocardial Infarction (MI), which share the same risk factors, treatments and pathophysiological mechanisms, have become two major public health problems due to the increase in their prevalence rate and the longer survival after such an event in developed countries.

International data, including French data and data from our own registries, illustrate that:

* risk factors that are common, mainly hypertension, smoking, high cholesterol or diabetes, remain insufficiently controlled, although they are easily detectable and treatable;
* the incidence rate of stroke has doubled in 20 years in people under 55 years of age, increasing the number of people with chronic disabilities;
* 1-month and 1-year mortality rates for stroke and MIs have decreased by 17% in 5 years, increasing the number of survivors but with chronic disabilities;
* the aging of the population and the arrival of the baby boomers of the 1950s in the at-risk age groups has increased the at-risk population;
* Stroke and MI recurrence rates reached a threshold of 6% / year, in contrast to the very high rates of re-hospitalization at 1 year: 30% post-stroke and 20% post-MI, due to poorly anticipated and controlled complications. These reasons explain the lack of significant progress in preventing recurrences, preventable complications (heart failure and arrhythmias after MI; falls, sphincter and swallowing disorders, dementia and arrhythmias after stroke) and re-admission. This observation is aggravated by problems of medical demography and therefore the availability of neurologists, cardiologists and general practitioners.

Local and foreign experiments have demonstrated the value of intensive, coordinated and multi-professional stroke and MI monitoring, including nurses, in terms of: better control of risk factors and reduction of the rate of re-hospitalization by recurrence in stroke follow-up; improvement of the patient's general condition, control of risk factors, reduction in the number of events, decrease in the number of re-hospitalizations and their duration in MI follow-up. The value of pharmacists' additional intervention in intensive post-MI follow-up compared to routine follow-up has also been demonstrated, particularly in terms of significant improvement in patient compliance.

The hypothesis is that 2 years of intensive follow-up for both post-stroke or post-MI patients, by trained hospital and liberal nurses, in conjunction with doctors and pharmacists, is of medico-economic interest compared to usual follow-up. Therefore a medico-economic evaluation was designed to evaluate the efficiency of this model, which combines community-based and recourse care, prevention and coordination of care compared to usual follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebrovascular Accidents Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stroke - usual follow-up

Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with regular follow-up

Usual follow-up

Intervention Type OTHER

2 medical consultations (nurse and doctor) over 24 months

Stroke - intensive follow-up

Patient with either primary stroke, recurrent stroke, hemorrhagic, ischemic or Transient Ischemic Attack (TIA) with intensive follow-up

Intensive follow-up

Intervention Type OTHER

10 medical visits (nurse, doctor, pharmacist) over 24 months

myocardial infarction - usual follow-up

Patient who has had a first or recurrent myocardial infarction with usual follow-up

Usual follow-up

Intervention Type OTHER

2 medical consultations (nurse and doctor) over 24 months

myocardial infarction -intensive follow-up

Patient who has had a first or recurrent myocardial infarction with intensive follow-up

Intensive follow-up

Intervention Type OTHER

10 medical visits (nurse, doctor, pharmacist) over 24 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Usual follow-up

2 medical consultations (nurse and doctor) over 24 months

Intervention Type OTHER

Intensive follow-up

10 medical visits (nurse, doctor, pharmacist) over 24 months

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient or legal representative who has given oral consent
* Patient over 18 years of age
* Patient with:

* either a primary MI or a recurrent MI, not previously included, defined according to the criteria of the European Society of Cardiology and ICD-10
* either a primary stroke, a recurrent stroke not previously included, hemorrhagic, ischemic or Transient Ischemic Attack (TIA), defined according to WHO criteria, the TOAST score and the ICD-10, with a Rankin score \< 5.
* Patient followed up in one of the 6 public health establishments of the GHT 21-52 (regional group of hospitals) or at the Valmy clinic in Dijon also participating in the project
* Patient with estimated survival beyond 12 months

Exclusion Criteria

* A patient who is not affiliated to the national health insurance system;
* A patient subject to legal protection (curatorship, guardianship)
* To be a patient subject to a measure of judicial safeguard;
* Pregnant, parturient or breastfeeding woman;
* Admitted for a condition other than stroke, TIA and MI;
* Experiencing heart failure before the MI;
* Be managed in EHPAD before and/or after stroke or IDM.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Dijon Bourgogne

Dijon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Bejot Y, Soilly AL, Bardou M, Duloquin G, Pommier T, Laurent G, Cottin Y, Vadot L, Adam H, Boulin M, Giroud M. Efficiency and effectiveness of intensive multidisciplinary follow-up of patients with stroke/TIA or myocardial infarction compared to usual monitoring: protocol of a pragmatic randomised clinical trial. DiVa (Dijon vascular) study. BMJ Open. 2023 Apr 26;13(4):e070197. doi: 10.1136/bmjopen-2022-070197.

Reference Type DERIVED
PMID: 37185649 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BEJOT Article 51

Identifier Type: -

Identifier Source: org_study_id